One in 12 Children With Lyme Disease Also Carry Powassan Virus Antibodies, Study Finds

One in twelve children evaluated for Lyme disease at eight U.S. emergency departments carried antibodies signaling recent Powassan virus infection, a study published November 18 in Clinical Infectious Diseases found.

The research, led by Boston Children’s Hospital and conducted through the Pedi Lyme Net network, identified serologic evidence of Powassan virus in 8.5% of children with confirmed Lyme disease versus 0.7% of matched controls — a fivefold increase in adjusted odds. None of the 26 co-infected children were diagnosed clinically at the time of care, CIDRAP reported.

“Our results support previous studies suggesting that the prevalence of [Powassan] infection is much higher than reported, particularly in patients with confirmed Lyme disease,” the authors wrote in the journal.

“Clinically unrecognized POWV infections were more common than previously acknowledged.”

the study concluded, noting that 39% of seropositive samples were confirmed by focus neutralization testing.

Flat-color vector editorial illustration of glass sample tubes in a rack beside a black-legged tick on a fern at a woodland
Photo: wisevoter.com

Same tick, faster transmission, different clinical picture

Both pathogens ride the Ixodes scapularis black-legged tick, but the transmission dynamics diverge sharply. Lyme disease requires at least 24 hours of attachment for the spirochete Borrelia burgdorferi to migrate from the tick’s gut to its salivary glands. Powassan virus, a flavivirus related to West Nile and tick-borne encephalitis viruses, resides in the salivary glands and can transmit in as little as 15 minutes.

This biological difference means a tick checks for Lyme may miss a Powassan exposure entirely. The virus was first identified in Ontario in 1958 and is recognized as a North American tick-borne encephalitis agent, though severe neuroinvasive disease remains rare in children.

Children with Lyme face 1 in 12 Powassan antibody rate

  • Children diagnosed with Lyme disease have a roughly 1 in 12 chance of also carrying antibodies to Powassan virus, suggesting simultaneous exposure.
  • Current commercial tests cannot reliably detect Powassan virus during the early, acute phase when clinical decisions are made.
  • If a child’s “Lyme” symptoms are atypical — persistent fever, neurologic signs, or failure to improve on doxycycline — clinicians should discuss Powassan testing with a public health laboratory.

Study design: nested case-control within a prospective cohort

Investigators analyzed biobanked specimens from 600 children under 21 years old evaluated for Lyme disease at eight emergency departments across endemic regions from 2015 through 2024. The cohort was 63% male with a median age of 9 years (interquartile range 6–14).

Researchers matched 305 children with early or early-disseminated Lyme disease to 295 “clinical mimics” — children with similar symptoms but negative Lyme testing — by age, sex, site, and presenting complaint. They applied a two-tier serologic algorithm (enzyme immunoassay followed by immunofluorescence assay) with confirmatory focus neutralization testing (FNT) and reverse transcriptase polymerase chain reaction (RT-PCR) on acute samples.

Group N Powassan Seropositive Prevalence (95% CI) Adjusted Odds Ratio (95% CI)
Lyme disease confirmed 305 26 8.5% (5.4–11.7%) 5.0 (1.2–21.9)
Clinical mimics (Lyme negative) 295 2 0.7% (0.1–2.4%) Reference

Eleven of the 26 seropositive Lyme cases (39%) were FNT-positive, strengthening the specificity of the finding. No RT-PCR tests returned positive, consistent with the brief, low-level viremia typical of flavivirus infections.

Diagnostic gap and the push for acute-phase assays

Serology reflects past exposure, not necessarily acute illness. The authors emphasized that the study does not establish how many co-infections were clinically significant. Current CDC-recommended testing relies on IgM/IgG immunoassays confirmed by plaque reduction neutralization testing (PRNT), which requires specialized biosafety level 3 facilities and weeks of turnaround.

The team called for faster, more accurate molecular or antigen-capture tests capable of detecting Powassan virus during the acute window — a capability that would change management for children presenting with encephalitis or aseptic meningitis in endemic areas.

No antiviral approved; commercial Lyme panels miss Powassan

  • No antiviral is approved; care is supportive.
  • Do not rely on commercial Lyme panels to rule out Powassan co-infection; they do not include it.

Funding, limitations, and next steps

Limitations acknowledged by the authors include potential misclassification of non-Lyme rashes as erythema migrans, the known insensitivity of early Lyme serology, and the possibility of false-positive Powassan serology due to cross-reactivity with other flaviviruses. Single time-point sampling prevented assessment of seroconversion or titer rise.

Founded on 20 July 1869 by Civil War surgeon Francis Henry Brown, Boston Children’s Hospital began as a 20-bed facility in Boston’s South End before moving to the Longwood Medical and Academic Area. It serves as the primary pediatric teaching hospital of Harvard Medical School and operates the world’s largest pediatric research enterprise, receiving more NIH funding than any other children’s hospital.

The Pedi Lyme Net team plans prospective surveillance incorporating acute-phase molecular testing to define the true incidence of symptomatic Powassan co-infection in children presenting with tick-borne illness.

References

  • Hadley SM, Woll CJ, Lee W, et al. Prevalence of Powassan Virus Infection in Children with Suspected Lyme Disease. Clin Infect Dis. 2026 Nov 18;ciag732. doi:10.1093/cid/ciag732.
  • Updated 2024.
  • Telford SR 3rd, et al. Emerg Infect Dis. 2019.
  • Feder HM Jr, et al. N Engl J Med. 2023.
  • CDC.
Photo of author

Health Desk

Health Desk at Archyde.

Scraffs Eliminated from X Factor Italy After Fourth Live Show